Discovery, Optimization, and Anticancer Activity of Lipid-Competitive Pleckstrin Homology Domain-Containing Family A...

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Phosphoinositide signaling pathways are crucial for cancer cell survival and proliferation.
• Current lipid kinase inhibitors face challenges due to on-target toxicity from pleiotropic signaling effects.
• Targeting specific phosphoinositide effector pathways offers a potential route to greater therapeutic specificity.

Purpose of the Study:

• To discover and characterize novel phosphoinositide-competitive inhibitors targeting the pleckstrin homology domain-containing A (PLEKHA) family.
• To explore the potential of inhibiting phosphoinositide effector pathways for cancer treatment.
• To investigate the efficacy of these inhibitors in melanoma cell lines.

Main Methods:

• *In silico* screening was employed to identify initial inhibitor candidates.
• Structure-activity relationship (SAR) optimization was performed to enhance compound potency.
• Cellular characterization was conducted to assess the biological effects of the novel inhibitors.

Main Results:

• Novel phosphoinositide-competitive inhibitors of the PLEKHA family were discovered.
• These compounds demonstrated cytotoxic effects in BRAF and NRAS mutant melanoma cells.
• The most potent inhibitor showed activation via endogenous esterase activity, indicating prodrug potential.

Conclusions:

• Targeting PLEKHA family PH domains with competitive inhibitors is a viable strategy for cancer therapy.
• Prodrug esters represent a promising approach for delivering inhibitors to phosphoinositide-binding pockets.
• This work opens new avenues for developing specific cancer therapeutics by modulating phosphoinositide signaling.